Your session is about to expire
← Back to Search
HSP90 inhibitor
PU-H71 for Myelofibrosis
Phase 1
Waitlist Available
Research Sponsored by Samus Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subject is willing and able to provide written informed consent before any study-specific procedures are performed.
Subject is willing to comply with all study procedures and restrictions.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights
Study Summary
This study is evaluating whether a drug may help patients with a rare blood disorder.
Eligible Conditions
- Myelofibrosis
- Primary Myelofibrosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Assess Safety and Tolerability of PU-H71
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Assess treatment response of PU H71
Trial Design
4Treatment groups
Experimental Treatment
Group I: Oral -100 mgExperimental Treatment1 Intervention
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Group II: Oral - 50mgExperimental Treatment1 Intervention
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Group III: Oral - 300 mgExperimental Treatment1 Intervention
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Group IV: Oral - 200 mgExperimental Treatment1 Intervention
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PU-H71
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Samus Therapeutics, Inc.Lead Sponsor
8 Previous Clinical Trials
72 Total Patients Enrolled
Michael Silverman, M.D.Study DirectorSamus Therapeutics
Hagop Youssoufian, M.D.Study DirectorSamus Therapeutics
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger